Item 16. Form 10-K Summary

4K characters. Original on sec.gov · Markdown

Item 16. Form 10-K Summary

Not applicable.

SCHEDULE II

AMPHENOL CORPORATION AND SUBSIDIARIES

VALUATION AND QUALIFYING ACCOUNTS

For the years ended December 31, 2022, 2021 and 2020

(Dollars in millions)


	Balance at		Charged to				Balance at
	beginning		cost and		Additions		end of
	of period		expenses		(Deductions)		period
Allowance for doubtful accounts:
Year ended December 31, 2022	$	43.5	$	20.2	$	0.2	$	63.9
Year ended December 31, 2021		44.8		1.5		(2.8)		43.5
Year ended December 31, 2020		33.6		8.5		2.7		44.8

Valuation allowance on deferred tax assets:
Year ended December 31, 2022	$	44.9	$	(1.1)	$	(1.6)	$	42.2
Year ended December 31, 2021		40.1		6.3		(1.5)		44.9
Year ended December 31, 2020		35.2		3.8		1.1		40.1

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized in the Town of Wallingford, State of Connecticut on the 8th day of February, 2023.


	AMPHENOL CORPORATION


	/s/ R. Adam Norwitt
	R. Adam Norwitt
	President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.


Signature	Title	Date


/s/ R. Adam Norwitt	President, Chief Executive Officer and Director	February 8, 2023
R. Adam Norwitt	(Principal Executive Officer)

/s/ Craig A. Lampo	Senior Vice President and Chief Financial Officer	February 8, 2023
Craig A. Lampo	(Principal Financial Officer and Principal Accounting Officer)

/s/ Martin H. Loeffler	Chairman of the Board of Directors	February 8, 2023
Martin H. Loeffler

/s/ David P. Falck	Presiding Director	February 8, 2023
David P. Falck

/s/ Nancy A. Altobello	Director	February 8, 2023
Nancy A. Altobello

/s/ Stanley L. Clark	Director	February 8, 2023
Stanley L. Clark

/s/ Edward G. Jepsen	Director	February 8, 2023
Edward G. Jepsen

/s/ Rita S. Lane	Director	February 8, 2023
Rita S. Lane

/s/ Robert A. Livingston	Director	February 8, 2023
Robert A. Livingston

	Director	February 8, 2023
Prahlad Singh*

/s/ Anne Clarke Wolff	Director	February 8, 2023
Anne Clarke Wolff

Dr. Singh was not a member of our Board of Directors during the reporting period. He was appointed to our Board on January 12, 2023.

Previous: Item 15. Exhibit and Financial Statement Schedules